InterMune clinches $55m deal to offload waning Actimmune
This article was originally published in Scrip
InterMune is to pocket $55 million plus royalties over two years by selling the rights to Actimmune (interferon gamma-1b) to Vidara Therapeutics International. The company noted that it had stopped investigating new uses for Actimmune several years ago, and has viewed it as a "tactical financial asset". Sales of the drug (around $4 million in the most recent quarter) have been in decline since the company settled charges of illegal off-label promotion for its use in idiopathic pulmonary fibrosis (IPF), which remains its key revenue driver despite the fact that it is not actively promoted and is still not licensed for the indication.
You may also be interested in...
Drug failures in Phase III and value-based pricing were two forces affecting Horizon and Vertex, respectively, last week. Biogen and Teva have shown that value, at least, is a force to be argued with.
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.